Le point sur les recommandations vaccinales pour les personnes âgées
Senior Vaccination Revolution: New shots Offer Protection Against deadly Diseases
Table of Contents
A decade ago, the vaccination landscape for Americans over 65 was starkly different. Now, a wave of new vaccines is offering unprecedented protection against a range of serious illnesses.
In 2015, the only vaccine recommended for seniors was the annual flu shot. Fast forward to 2025, and four new vaccines have been added to the recommended schedule, dramatically expanding protection for this vulnerable population.
“We’ve seen a true revolution in senior vaccinations,” says Dr. Anne-Claude Crémieux, president of the Technical Vaccination Committee at the French Haute Autorité de santé (HAS). “In addition to the flu vaccine, we now have vaccines against COVID-19, shingles, respiratory syncytial virus (RSV), and a new pneumococcal vaccine.”
Shingles: A Painful Threat Now Preventable
One of the most meaningful advancements is the new shingles vaccine, Shingrix.
“The older shingles vaccine was less effective and didn’t offer long-lasting protection,” explains Dr.crémieux. “Shingrix, a recombinant vaccine, is much more effective, offering about 80% protection against shingles and 76% protection against the debilitating pain that can linger after a shingles outbreak.”
Shingles, caused by the reactivation of the chickenpox virus, can be notably risky for seniors.
“The risk of shingles increases with age,and the complications can be severe,” says Dr. Crémieux. “Over 50% of people over 80 will experience shingles, and it can lead to hospitalization, especially in those over 65. Sadly, 94% of shingles-related deaths occur in people over 70.”
While Shingrix has been shown to be highly effective and safe, it can cause more side effects than the older vaccine.However, the benefits far outweigh the risks, according to Dr.Crémieux.Protecting Seniors from RSV and Pneumococcal Disease
The new RSV vaccine and the updated pneumococcal vaccine offer further protection against serious respiratory illnesses. RSV, a common respiratory virus, can be particularly dangerous for seniors, leading to pneumonia and hospitalization. The new pneumococcal vaccine provides broader protection against different strains of the bacteria, which can cause pneumonia, meningitis, and sepsis.
These new vaccines represent a major step forward in protecting the health and well-being of America’s seniors. By staying up-to-date on recommended vaccinations, seniors can significantly reduce their risk of serious illness and enjoy a healthier, more active life.
New Vaccines Offer hope Against Respiratory Threats for Seniors
As flu season approaches, experts are urging seniors to consider new vaccines that offer protection against two serious respiratory illnesses: Respiratory Syncytial Virus (RSV) and pneumococcal disease.
Dr. Anne-Laure Crémieux, president of the Technical Committee on Vaccinations (CTV), highlights the growing threat these diseases pose to older adults. “RSV can be particularly dangerous for seniors,often leading to hospitalizations and even death,” she explains.”While we’ve known about RSV’s impact on nursing homes for years, the severity increases significantly after age 75.”
Adding to the concern,Dr.Crémieux notes that existing health conditions can worsen RSV’s effects. “About 80% of hospitalizations in France due to RSV are linked to complications from pre-existing heart and lung conditions,” she warns.
New RSV Vaccines Offer Hope
Fortunately, recent advancements in vaccine technology offer new hope.Three new RSV vaccines have been approved in Europe, including two protein-based vaccines (Arexvy and Abrysvo) and one mRNA vaccine (mResvia).While Abrysvo is currently covered by insurance for pregnant women to protect newborns, the other two vaccines are not yet reimbursed. Dr. Crémieux emphasizes the importance of vaccination for seniors, recommending it for everyone over 75 and encouraging consideration for those over 65 with underlying health conditions.”Protein-based RSV vaccines have shown effectiveness rates between 67% and 83% in preventing lower respiratory tract infections with two or three symptoms,” she explains.
Pneumococcal Vaccine Strategy Overhauled
Another respiratory threat, pneumococcal disease, also disproportionately affects seniors. While previously targeted primarily at children under two, Dr. Crémieux points out that infection rates are now higher in adults over 65.
Acknowledging the limitations of a risk-based vaccination strategy, which has resulted in a coverage rate of less than 5%, the CTV has recommended a change.
“The arrival of a new 20-valent pneumococcal conjugate vaccine (PCV20) has allowed us to revise our strategy,” Dr. Crémieux explains. “This vaccine, reimbursed as March 7, 2024, protects against 60% of the pneumococcal serotypes responsible for invasive infections, compared to 30% less coverage by the previous vaccine.”
Protecting Seniors: A Multi-Pronged Approach
As flu season approaches, Dr. Crémieux stresses the importance of a multi-pronged approach to protect seniors. ”Vaccination against RSV, pneumococcal disease, and influenza is crucial,” she urges.”Combined with good hygiene practices and social distancing, these measures can significantly reduce the risk of serious respiratory illness in older adults.”
Boosting Immunity: Experts Call for Expanded Vaccination Efforts for Seniors
New recommendations aim to protect vulnerable populations from preventable diseases.
As flu season approaches and concerns about respiratory illnesses remain high, health experts are urging Americans, particularly seniors, to prioritize vaccinations.
dr. Anne-Laure Crémieux, president of the Committee on Vaccine-Preventable Diseases, emphasized the importance of thorough protection.”We reccommend a single dose of the 20-valent pneumococcal vaccine for unvaccinated individuals,” she stated. “This can be administered alongside COVID-19 and flu vaccines for added convenience.”
Dr.Crémieux highlighted the vaccine’s long-lasting effectiveness, noting it provides protection for at least five years.However, she stressed the need for further action.
“This alone is not enough,” she explained. “We need to establish new guidelines that consider age as a key risk factor. Half of all invasive pneumococcal infections occur in individuals over 65. Thus, we strongly recommend expanding pneumococcal vaccination to everyone aged 65 and older.”
Dr. Crémieux underscored the crucial role vaccines play in safeguarding the health of older adults. “Vaccines are essential tools for reducing hospitalizations and promoting well-being in seniors,” she said. “While no vaccine is perfect, as we’ve seen with COVID-19 and influenza, pneumococcal vaccines offer robust protection. The real challenge lies in increasing vaccination rates, which are currently very low.”
Echoing the World Health association’s stance, Dr. Crémieux expressed optimism about the future of vaccine development. “Research into next-generation flu vaccines is ongoing, and we anticipate the arrival of improved options soon,” she concluded.
Senior Vaccination revolution: An Interview with Dr. Anne-Claude Crémieux
(NewsDirectory3.com) - In a landmark advancement for senior health, a wave of new vaccines is transforming the landscape of protection against deadly diseases for Americans over 65. Just a decade ago, the only recommended vaccine for this age group was the annual flu shot. Now, four new vaccines are bolstering protection against a range of serious illnesses.
We sat down with Dr. Anne-Claude Crémieux, president of the technical Vaccination Committee at the French Haute Autorité de santé (HAS), to discuss this “true revolution” in senior vaccinations.
NewsDirectory3.com: dr. Crémieux, what are the most meaningful changes in senior vaccinations over the past decade?
Dr. Crémieux: The progress has been remarkable. Along with the flu shot, we now have vaccines against COVID-19, shingles, respiratory syncytial virus (RSV), and a new pneumococcal vaccine. This broadened immunization strategy significantly reduces the risk of serious illnesses for seniors.
NewsDirectory3.com: The new shingles vaccine, Shingrix, has garnered a lot of attention. Can you elaborate on its importance?
Dr. Crémieux: Shingrix is a game-changer. The older shingles vaccine was less effective and provided limited long-term protection. Shingrix, a recombinant vaccine, offers impressive protection – around 80% against shingles itself and 76% against the debilitating pain that can persist after a shingles outbreak.
NewsDirectory3.com: The risks associated with shingles, particularly for seniors, are concerning.
Dr. crémieux: Absolutely. The risk of shingles increases with age, and complications can be severe. Over half of individuals over 80 will experience shingles, and it can lead to hospitalization, especially in those over 65. Tragically, 94% of shingles-related deaths occur in people over 70.
NewsDirectory3.com: Beyond shingles, what other threats do these new vaccines address?
dr. Crémieux: The new RSV vaccine and the updated pneumococcal vaccine offer crucial protection against serious respiratory illnesses. RSV, a common respiratory virus, can be particularly hazardous for seniors, often resulting in pneumonia and hospitalization.
The pneumococcal vaccine provides broader protection against various strains of bacteria that cause pneumonia, meningitis, and sepsis, illnesses that can be particularly devastating for older adults.
NewsDirectory3.com: What message do you have for seniors regarding these new vaccines?
Dr. Crémieux:
Staying up-to-date on recommended vaccinations is a cornerstone of healthy aging. These new vaccines offer unparalleled protection against potentially life-threatening illnesses and empower seniors to live healthier, more active lives. Talk to your doctor about these vaccines and make an informed decision about your health.
(NewsDirectory3.com) – The future of senior health looks brighter thanks to these advancements in vaccination. For more data about recommended vaccines and their availability, consult with your healthcare provider.